Found 187 clinical trials
Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis
This proposal translates a hypothesis driven basic research into clinical setting to determine the potential of using autologous CD133+ cells to reverse fibrosis and improve clinical outcome for patients with end stage cirrhosis. This has significant impact on the management of cirrhosis.
- 27 views
- 25 Feb, 2022
- 1 location
Comparison of Hypothermic Versus Normothermic Ex-vivo Preservation. (DCDNet)
Study groups: The study is a multicenter (Pisa and Milan), prospective, randomized study comparing D-HOPE (HMP) vs NMP in DCD and ECD-DBD (extended criteria brain-dead donors). Once a DCD or a DBD with extended criteria (ECD-DBD) meets the inclusion criteria, they are randomized as follow: 20 liver grafts from DCD …
- 0 views
- 16 Mar, 2022
- 1 location
Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan-hziy in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
The primary objectives of this study are to identify the safe starting dose of sacituzumab govitecan-hziy, assess the number of participants with antibodies against sacituzumab govitecan-hziy, and evaluate the pharmacokinetics (PK) of sacituzumab govitecan-hziy, free SN-38, SN-38 glucuronide (SN-38G), total SN-38, in participants with solid tumor and moderate hepatic impairment.
- 0 views
- 13 Jun, 2022
- 6 locations
Lactoferrin in Treatment of Fe Deficient Anemia In Cirrhosis
Iron deficiency and altered homeostasis due to inflammation and decreased iron utilization are main factors involved in anemia in liver disease. Lactoferrin is a first line defence protein for protection against microbial infections and subsequent development of systemic disease as seen with systemic inflammatory response syndrome (SIRS) and sepsis. Lactoferrin …
- 22 views
- 03 Mar, 2022
- 1 location
Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy
A total of 40 patients taking proton pump inhibitors (PPIs) who undergo transjugular intrahepatic portosystemic shunt (TIPS) creation as part of routine clinical care will be randomized in 1:1 fashion to either continue or discontinue their PPIs to determine whether these commonly used gastric acid suppressing agents increase risk of …
- 0 views
- 22 Mar, 2022
- 1 location
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3131)
Study RNLC3131 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in advanced liver cirrhosis, defined by the presence of medically controlled ascites.
- 0 views
- 28 Apr, 2022
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients (LIBERATE)
The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of allograft rejection following immunosuppression withdrawal in liver transplantation. QEL-001 is a product made from a liver transplant recipient's own immune cells, which are genetically modified and designed to help the transplant recipient's …
- 0 views
- 24 Mar, 2022
- 1 location
The Influence of Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy
Through a multicenter randomized controlled trial of TIPS to prevent post-hepatitis B cirrhosis of esophagogastric varices, the incidence of hepatic encephalopathy, the rate of stent patency, the incidence of rebleeding and survival in the left and right branches of the portal vein were compared.
- 2 views
- 15 Feb, 2022
Rifamycin in Minimal Hepatic Encephalopathy
This is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis using rifamycin SV-MMX 600mg BID vs placebo for 30 days with PK, safety, microbiota, brain function and brain MRI endpoints.
- 5 views
- 22 Mar, 2022
- 1 location
FMT in Cirrhosis and Hepatic Encephalopathy
Patients with end stage of liver disease or cirrhosis can develop confusion due to high ammonia and inflammation. This confusion is brought upon by changes in the bacteria in the bowels and may not respond to current standard of care treatments. Repeated episodes of confusion can make it difficult for …
- 41 views
- 05 Apr, 2022
- 1 location